A report from S&P Global Ratings predicts biosimilar sales will increase nearly threefold to over $6.5 billion in 2024 from around $2.5 billion last year. Biosimilars are expected to make up 2.5% of overall biopharmaceutical sales by 2024, according to the analysis, which didn't include sales from Novartis' Sandoz unit, meaning the estimates might be low.
Report forecasts biosimilar sales to top $6.5B in 2024
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.